Other News To Note
Friday, April 19, 2013
Epizyme Inc., of Cambridge, Mass., said it signed a deal with Abbott, of Abbott Park, Ill., to develop a molecular companion diagnostic test for use with EPZ-5676, its inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.